Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05786521 · ClinicalTrials.gov registry record · Phase 4
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT05786521 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 20 participants.
The verdict
NCT05786521, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Interventions
- BEHAVIORAL Lifestyle Counseling
- DRUG Semaglutide Injectable Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2024-05-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05786521
The ClinicalTrials.gov registry entry for NCT05786521 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lifestyle Counseling is the first listed.
NCT05786521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05786521 about?
NCT05786521 is a clinical study titled "Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults". Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect...
What is the current status of trial NCT05786521?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-04-01. Estimated completion is 2024-05-20.
What interventions are being tested in trial NCT05786521?
The interventions under investigation include: Lifestyle Counseling (BEHAVIORAL), Semaglutide Injectable Product (DRUG).
Who is sponsoring clinical trial NCT05786521?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.